These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 1280568)

  • 1. Cefodizime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
    Barradell LB; Brogden RN
    Drugs; 1992 Nov; 44(5):800-34. PubMed ID: 1280568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cefpodoxime proxetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential.
    Frampton JE; Brogden RN; Langtry HD; Buckley MM
    Drugs; 1992 Nov; 44(5):889-917. PubMed ID: 1280571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ceftizoxime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
    Richards DM; Heel RC
    Drugs; 1985 Apr; 29(4):281-329. PubMed ID: 3888599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ceftriaxone. A review of its antibacterial activity, pharmacological properties and therapeutic use.
    Richards DM; Heel RC; Brogden RN; Speight TM; Avery GS
    Drugs; 1984 Jun; 27(6):469-527. PubMed ID: 6329638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro antimicrobial activity of cefodizime, a third generation cephalosporin.
    Pruksachatvuthi S; Aswapokee N; Aswapokee P
    J Med Assoc Thai; 1992 May; 75(5):287-92. PubMed ID: 1460409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cefdinir: a review of its use in the management of mild-to-moderate bacterial infections.
    Perry CM; Scott LJ
    Drugs; 2004; 64(13):1433-64. PubMed ID: 15212560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cefuroxime axetil: an updated review of its use in the management of bacterial infections.
    Scott LJ; Ormrod D; Goa KL
    Drugs; 2001; 61(10):1455-500. PubMed ID: 11558834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cefodizime once daily in the treatment of lower respiratory tract infections.
    Piovano CF; Palombini BC; Dagrosa EE; Mendoza F; Facco EB
    Arzneimittelforschung; 1997 May; 47(5):674-7. PubMed ID: 9205786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cefepime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
    Barradell LB; Bryson HM
    Drugs; 1994 Mar; 47(3):471-505. PubMed ID: 7514976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Azithromycin. A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy.
    Peters DH; Friedel HA; McTavish D
    Drugs; 1992 Nov; 44(5):750-99. PubMed ID: 1280567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levofloxacin: a review of its use in the treatment of bacterial infections in the United States.
    Croom KF; Goa KL
    Drugs; 2003; 63(24):2769-802. PubMed ID: 14664657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cefotaxime. A review of its antibacterial activity, pharmacological properties and therapeutic use.
    Carmine AA; Brogden RN; Heel RC; Speight TM; Avery GS
    Drugs; 1983 Mar; 25(3):223-89. PubMed ID: 6303743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [In vitro antibacterial activity of cefodizime (HR 221) on 323 hospital strains of Gram negative bacilli. Comparison with cefotiam, cefoperazone, cefotetan and cefotaxime].
    Le Noc P; Bryskier A; Le Noc D
    Pathol Biol (Paris); 1985 May; 33(5):399-403. PubMed ID: 3897972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy.
    Davis R; Bryson HM
    Drugs; 1994 Apr; 47(4):677-700. PubMed ID: 7516863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fleroxacin. A review of its pharmacology and therapeutic efficacy in various infections.
    Balfour JA; Todd PA; Peters DH
    Drugs; 1995 May; 49(5):794-850. PubMed ID: 7601015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo activity of cefodizime.
    Shah PM; Knothe H
    Infection; 1992; 20 Suppl 1():S9-13. PubMed ID: 1526686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized comparative study of 0.5 and 1 g of cefodizime (HR 221) versus 1 g of cefotaxime for acute uncomplicated urogenital gonorrhea.
    van der Willigen AH; Wagenvoort JH; Schalla WO; Knapp JS; Boot JM; Heeres-Weststrate PL; Michel MF; van Klingeren B; Stolz E
    Antimicrob Agents Chemother; 1988 Apr; 32(4):426-9. PubMed ID: 3377456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Review of oral cephalosporins. Basis for a rational choice].
    Forti IN
    Medicina (B Aires); 1994; 54(5 Pt 1):439-58. PubMed ID: 7658980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cefotaxime. A pharmacoeconomic review of its use in the treatment of infections.
    Plosker GL; Foster RH; Benfield P
    Pharmacoeconomics; 1998 Jan; 13(1 Pt 1):91-106. PubMed ID: 10175990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cefmenoxime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
    Campoli-Richards DM; Todd PA
    Drugs; 1987 Aug; 34(2):188-221. PubMed ID: 3304966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.